secwatch.observer — SEC 8-K summary
======================================

Issuer:     PFIZER INC (PFE)
CIK:        0000078003
Form:       8-K/A
Filed at:   2023-12-14T23:59:59+00:00
Accession:  0001193125-23-295562
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pfizer completes $43B acquisition of Seagen; Seagen becomes wholly owned subsidiary
--------------------------------------------------------------------------------

- Acquisition closed Dec 14, 2023; $229 per share in cash for total enterprise value approx. $43 billion.
- Adds Seagen's four approved medicines (ADCETRIS, PADCEV, TIVDAK, TUKYSA) and ADC technology.
- Pfizer's oncology pipeline doubled to 60 programs across multiple modalities.
- To address FTC concerns, Pfizer irrevocably donated U.S. royalty rights from Bavencio (avelumab) to AACR.
- Pfizer's oncology portfolio now includes over 25 approved medicines and biosimilars across >40 indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/78003/000119312523295562/0001193125-23-295562-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/78003/000119312523295562/d612444d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-295562

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer